Please login to the form below

What do NHS changes and the Life Sciences Vision mean for medicines?

With the publication of the new Life Sciences Vision, a new NHS Bill, and new Health Secretary and NHS England Chief Executive, there are many fresh additions to add to the blur of change in the NHS. But what do they mean for medicines? In his latest blog, Hanover Health’s Andrew Harrison argues that there is a need for a renewed value story for medicines in the NHS, one which articulates their contribution to the prevention agenda and how they can relieve the burden of care on the health system.

With the publication of a new Life Sciences Vision (LSV), the first major piece of health legislation in nine years and a new Health Secretary and NHS England Chief Executive, there are many fresh additions to the blur of change in the NHS. But what do they mean for medicines and industry’s value story?

The launch of a new life sciences strategy is an important and positive step for industry. It sets out a cross-government approach to achieving the ambition of making the UK a life sciences superpower. In contrast to the 2017 Life Sciences Industrial Strategy, the LSV is a Government publication endorsed by the Department of Health and Social Care (DHSC) and NHS England - the LSIS was a series of industry recommendations to the Government. The LSV also clearly states the ambition to “make the NHS the country’s most powerful driver of innovation – through the development, testing and adoption of new technologies at a population scale.”

The LSV does not sit in isolation, it is a key part of the Government’s economic recovery strategy and is closely tied to the Plan for Growth and forthcoming Innovation Strategy. It also rightly supports the Government’s ambitions in health by identifying the role of life sciences in addressing seven ‘great health challenges’ for the UK population.

These seven challenges (or ‘’silent pandemics’ as the LSV calls them) are neurodegeneration; early diagnosis and treatment in cancer, including immune therapies; vaccine development and manufacturing; cardiovascular disease and obesity; respiratory disease; the underlying biology of ageing; and mental health. Also threaded through the strategy is the drive to increase research in the NHS and the harnessing of genomic and health data for this purpose.

All this is very positive. But there is always a question when reviewing new strategies – how much of it will be implemented?

Previous strategies show that whilst the Government has been able to make changes to the research and skills environment, progress on the adoption of medicines in the NHS has been slower. A government review in 2005 noted the low and slow use of medicines in the NHS, and half a dozen life science strategies later, the problem is still to be fixed.

The NHS rightly focused on pandemic recovery and record waiting lists. Companies need to clearly articulate how therapies relieve the burden on the NHS, particularly hospital-based care.

An NHS rightly focused on pandemic recovery, record waiting lists and implementing new structural changes will need strong incentives and direction from DHSC if the NHS elements of LSV are to be achieved. Ahead of the next election, DHSC Ministers will share the NHS’s focus if the Government is to avoid the potential political backlash from up to 1 in 4 adults in England waiting for NHS treatment.

Ministers will need to set clear goals for the NHS’s implementation of the LSV. And a cross Government effort to retain the connected health and economic benefits of the LSV will be needed to ensure DHSC and NHS accountability.

For industry, there is also a role to play, and companies should consider how their value story may need to evolve.

The LSV restates the NHS Long Term Plan’s narrative of the need for prevention, population health and better management of chronic conditions, for the benefit of patients but also the sustainability of the NHS. Companies have a major role to play in this need to clearly articulate their role.

Rare disease, advanced and specialist therapies have sometimes been seen as a burden for payers focused on other bigger priorities for larger patient populations. Meanwhile, the value story from industry has often led with the patient benefit addressing unmet need. Patient benefit is of course crucial, but therapies need to more clearly and prominently explain how they relieve the patient burden on the NHS, particularly on hospital-based care. Now is the time to show how these innovations can free up vital space in acute care by preventing or reducing the number of planned or unplanned patient visits to hospital and demands on staff time.

During the pandemic we saw how local NHS clinicians were quick to adopt and switch to treatments that reduced pressure on the NHS, reworking formularies and choosing newer and sometimes more expensive treatment (even going outside of NICE guidance) because of this prioritised aspect of product value. One senior NHS hospital manager told me recently, “if a treatment can help with recovery of elective care, then you have my attention.”

Industry must maintain its advocacy with the new leaders at the top of the NHS and Government to ensure clear incentives are in place to drive the LSV. But it is also up to every company and every brand to communicate their value story more clearly to a health service under incredible pressure. To be successful in this new world, industry must be the partner of choice it always aspires to be.

20th September 2021

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications